Skip to Main Content

Where are all the biotech buyouts?

We’re two days into the real start of 2020, the J.P. Morgan Healthcare Conference is fast approaching, and some of biotech’s most buzzed-about acquisition targets have already been crossed off the “deal imminent” list.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!